| | Funded Clinical Trials/Research | - Risk Mediators of Metabolic Syndrome and Non-Alcoholic Steatohepatitis (NASH). Principal investigator: Dr. Still.
- Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of L-000753721 in Obese, Non-Diabetic Patients. Principal investigator: Dr. Still.
- CRESCENDO - Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes. Randomized, multinational, multi-center, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors. Principal investigator: Dr. Still.
- GALIANT – Novartis – CLAF237A23119: A multi-center, randomized, open-label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with vildagliptin 100 mg qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community-based practice setting. Principal investigator: Dr. Still.
- Geisinger Rural Aging Study (GRAS). Principal investigator: Dr. Still.
- BLOOM APD 356-009: Behavioral Modification and Lorcaserin for Overweight and Obesity Management. Principal investigator: Dr. Still.
|
|
